Greywolf Therapeutics
Natalie Hyland currently serves as the Head of Clinical Operations at Greywolf Therapeutics since February 2023. Prior to this, Natalie held the position of Senior Director, Early Clinical Lead at Adaptimmune from March 2017 to February 2023. Natalie's experience also includes roles such as Director, Clinical Scientist at Bio Products Laboratory Limited, Clinical Project Leader at GSK, and Clinical Study Manager positions at both Cancer Research UK and Amgen. Additional experience encompasses Clinical Research Associate at Kendle International Inc, Clinical Trial Coordinator at Holdsworth House Medical Practice, GSK, and Hammersmith Medicines Research Ltd. Natalie Hyland graduated from the University of Leeds in 2001.
This person is not in any teams
Greywolf Therapeutics
Many cancers and other diseases are caused, or resist treatment, because T cells can't recognize or target cells correctly. We're progressing first-in-class antigen modulators through the clinic, developed to treat disease by controlling T cell activation. Our technology modulates antigen presentation, flicking a switch inside cells to alter their appearance to the immune system. This approach marks a fundamental shift in how we treat people living with autoimmune disorders, cancers and infectious diseases.